Oxurion (TBGNF) Stock Price, News & Analysis

Company Overview

Oxurion is a Belgium-based biotechnology company specializing in the development and commercialization of therapeutics for retinal disorders. Formerly known as ThromboGenics NV, the company rebranded as Oxurion in 2019 to reflect its broader focus on ophthalmology and advanced drug discovery platform capabilities. Oxurion’s research efforts are centered on identifying and advancing novel candidates that address unmet needs in diseases such as diabetic macular edema (DME), wet age-related macular degeneration (AMD) and other vision-threatening conditions.

Among Oxurion’s most notable products is JETREA® (ocriplasmin), an enzyme therapy that enables non-surgical treatment of symptomatic vitreomacular adhesion. JETREA is marketed through licensing agreements in key territories, including the United States, Europe and parts of Asia. In addition to its commercial product, Oxurion maintains a preclinical and clinical pipeline that includes proprietary small molecules and biologics aimed at regulating vascular leakage, inflammation and tissue remodeling in the retina.

Oxurion operates from its headquarters in Mechelen, Belgium, with research and corporate offices strategically located in the United States and other European countries. The company collaborates with academic institutions, contract research organizations and global pharmaceutical partners to advance its programs through clinical development. Oxurion’s multidisciplinary team brings together expertise in ophthalmology, molecular biology and drug delivery to drive innovation in sight-saving therapies.

Since its inception in 2005, Oxurion has established a track record of strategic licensing and development transactions designed to maximize the therapeutic potential of its candidates and generate milestones and royalties. By focusing exclusively on retinal disease and leveraging cutting-edge science, Oxurion aims to deliver new treatment options that improve patient outcomes and address the growing global burden of visual impairment.

Key Stats

• Today's Range: $0.17 to $0.17
• 50-Day Range: $0.17 to $0.17
• 52-Week Range: $0.17 to $0.29
• Volume: N/A
• Average Volume: 440 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TBGNF Stock Analysis - Frequently Asked Questions

How have TBGNF shares performed this year?

Oxurion's stock was trading at $0.17 at the beginning of the year. Since then, TBGNF stock has increased by 0.0% and is now trading at $0.17.

How do I buy shares of Oxurion?

Shares of TBGNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:TBGNF
• CIK: N/A
• Web: www.oxurion.com
• Phone: (321) 675-1317
• Fax: N/A
• Employees: 27
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A